Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment 23 November 2022 Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now.
Studies find Omicron related hospitalisations lower in severity than Delta and Pfizer-BioNTech COVID vaccine remains effective in preventing hospitalisations 12 December 2022 Adult hospitalisations from Omicron-related SARS-CoV-2 (COVID-19) were less severe than Delta and the Pfizer-BioNTech vaccine (also known as Comirnaty and BNT162b2*) remains effective in preventing not only hospitalisation, but severe patient outcomes associated with COVID-19, two new research studies have found.
#CORONAVIRUS NEW FINDINGS HOW TO#
Bristol study finds third COVID-19 "booster" is associated with a substantial increase in antibodies 24 January 2023 A national study involving Bristol’s Children of the 90s has found the "booster" vaccine led to a substantial increase in the antibodies that help protect against coronavirus.However, there is a trade-off, where this same variation is also linked to increased autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Genetic variation that protected against Black Death still helps protect against infection but increases autoimmune disease 7 March 2023 The same genetics that helped some of our ancestors fight the plague is still likely to be at work in our bodies today, potentially providing some of the population with extra protection against respiratory diseases such as COVID-19, according to research led by scientists at University of Bristol.£1.5 million investment to bring Bristol spin-out Halo Therapeutics first antiviral spray into clinic Clinical trials of an easy-to-use home therapeutic treatment for SARS-CoV-2 (coronaviruses) are underway following a £1.5 million investment into University of Bristol spin-out, Halo Therapeutics.
0 kommentar(er)
